Press releaseGlobe Newswire
Tarsus Pharmaceuticals
TARS · NASDAQ
$71.03+$1.53 (+2.20%)TodayMarket closed ·
Prev close $69.50
Latest news
- Press releaseGlobe Newswire
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
- Press releaseGlobe Newswire
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
- NewsVandana Singh
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
- Press releaseGlobe Newswire
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
- NewsEvette Mitkov
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme
- Press releaseGlobe Newswire
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
- News
Earnings Scheduled For May 6, 2026
- Press releaseGlobe Newswire
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
- News
Tarsus Pharmaceuticals Announces $15M Milestone Payment Achieved After Regulatory Approval Of TP-03 By China's National Medical Products Administration
- Press releaseGlobe Newswire
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
- NewsAvi Kapoor
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
- News
Insights into Tarsus Pharmaceuticals Q4 Earnings
- Press releaseGlobe Newswire
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
- News
Earnings Scheduled For February 23, 2026
- News
Earnings Preview: Tarsus Pharmaceuticals
- Press releaseBusiness Wire
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
- News
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- Press releasePRNewswire
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
- News
An Overview of Tarsus Pharmaceuticals's Earnings
- Press releaseBusiness Wire
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
- Press releaseBusiness Wire
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
- News
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
- NewsAvi Kapoor
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
- News
Earnings Outlook For Tarsus Pharmaceuticals
- NewsAvi Kapoor
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.